<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30148">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01954017</url>
  </required_header>
  <id_info>
    <org_study_id>STP206-002</org_study_id>
    <nct_id>NCT01954017</nct_id>
  </id_info>
  <brief_title>STP206 for the Prevention of NEC</brief_title>
  <official_title>A Phase Ib/IIa Randomized, Placebo Controlled Study of the Safety and Efficacy of Once Daily Dosing of STP206 in Premature Very Low Birth Weight and Extremely Low Birth Weight Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sigma Tau Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sigma Tau Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted in two parts.  Part A will be a sequential dose escalation study
      to determine the safety and tolerability of two doses of STP206 versus control. Part B will
      evaluate safety and NEC preventive efficacy of STP206 in VLBW and ELBW neonates.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>To assess the safety and tolerability of once daily dosing of two dose levels of STP206 versus control in four different birth weight strata in premature neonates.</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the fecal shedding after daily dosing of each component of STP206 throughout the dosing phase</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the incidence of NEC in STP206-treated subjects compared to control</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the incidence of clinical events (sepsis/bacteremia, feeding intolerance, morbidity/complications of prematurity) in STP206-treated subjects compared to control</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the progression of standard neonatal growth parameters in STP206-treated subjects compared to control</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Necrotizing Enterocolitis</condition>
  <arm_group>
    <arm_group_label>STP 206</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile water</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>STP 206</intervention_name>
    <description>Live Biotherapeutic</description>
    <arm_group_label>STP 206</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sterile Water</intervention_name>
    <arm_group_label>Sterile Water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Neonates with birth weights between 2000-500g for Part A and 1500-500g for Part B

          2. Ability to start treatment within four days after birth.

          3. Gestational age between 23 and 32 weeks at birth

          4. Obtaining of informed consent from the subject's mother after full understanding of
             the study purpose and procedures.

          5. Parents who agree to allow the Principal Investigator and his/her staff to follow the
             procedures and assessments required by the protocol

        Exclusion Criteria:

          1. Infants with, or at high probability for, early onset sepsis (positive blood cultures
             or with clinical/histological chorioamnionitis with the expectation of empirical
             antimicrobial therapy for â‰¥5 days)

          2. Infants with persistent pulmonary hypertension of the newborn (PPHN)

          3. Congenital or chromosomal anomalies

          4. Congenital or acquired gastrointestinal pathology that preclude feeds soon after
             birth (e.g. cleft lip is not an exclusion criterion, but a duodenal atresia is)

          5. Infants in extremis to whom no further intensive care is offered by attending
             neonatologist (e.g., infant being provided only hospice/comfort care)

          6. Other conditions of the infant which, in the opinion of the attending neonatologist,
             preclude participation

          7. Positive maternal HIV status
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S Caplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Rodgers, MS, CCRA</last_name>
    <phone>301-670-1565</phone>
    <email>Scott.Rodgers@sigmatau.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Genna, R.Ph.</last_name>
    <phone>301-670-1516</phone>
    <email>thomas.genna@sigmatau.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy L Frost, MD</last_name>
      <phone>847-570-2530</phone>
    </contact>
    <investigator>
      <last_name>Brandy L Frost, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wesley Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Delmore, MSN</last_name>
      <phone>316-962-8555</phone>
    </contact>
    <investigator>
      <last_name>Barry T Bloom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula G Radmacher, Ph.D.</last_name>
      <phone>502-852-5532</phone>
      <email>paula.radmacher@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>, .</last_name>
    </contact_backup>
    <investigator>
      <last_name>David H Adamkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>September 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
